Stem cell-based therapies for the newborn lung and brain: Possibilities and challenges

Seminars in Perinatology

Volumn 40, Issue 3, 2016, Pages 138-151

  Mitsialis, S Alex ^a,b   Kourembanas, Stella ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bronchopulmonary dysplasia; Exosomes; Hypoxic ischemic encephalopaty; Mesenchymal stem cells

Indexed keywords

ADIPOCYTE; AMNION CELL; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMING CELL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE EXACERBATION; EMBRYONIC STEM CELL; ENCEPHALOMALACIA; EXOSOME; GENETIC MANIPULATION; GESTATIONAL AGE; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IN VITRO STUDY; IN VIVO STUDY; LUNG DYSPLASIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NEWBORN MORBIDITY; NONHUMAN; NUCLEAR REPROGRAMMING; OLIGODENDROGLIA; OPEN STUDY; OSTEOBLAST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREMATURITY; PRIORITY JOURNAL; PROTEOMICS; RECURRENT DISEASE; REVIEW; RISK FACTOR; TH17 CELL; TH2 CELL; ADVERSE DRUG REACTION; ADVERSE EFFECTS; BRONCHOPULMONARY DYSPLASIA; CLASSIFICATION; HYPOXIA-ISCHEMIA, BRAIN; METABOLISM; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL; STEM CELL TRANSPLANTATION; THEORETICAL MODEL; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

BRONCHOPULMONARY DYSPLASIA; EXOSOMES; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; LONG TERM ADVERSE EFFECTS; MODELS, THEORETICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84954306749     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.12.002     Document Type: Review

References (150)

1. Stoll B.J., Hansen N.I., Bell E.F., et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. J Am Med Assoc 2015, 314(10):1039-1051.
2. Northway W.H., Rosan R.C., Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967, 276(7):357-368.
3. Khemani E., McElhinney D.B., Rhein L., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007, 120(6):1260-1269.
4. del Cerro M.J., Sabate Rotes A., Carton A., et al. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr Pulmonol 2014, 49(1):49-59.
5. Bassler D., Plavka R., Shinwell E.S., et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 2015, 373(16):1497-1506.
6. Kurinczuk J.J., White-Koning M., Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev 2010, 86(6):329-338.
7. Shankaran S., Laptook A.R., Ehrenkranz R.A., et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005, 353(15):1574-1584.
8. Baker C.D., Balasubramaniam V., Mourani P.M., et al. Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia. Eur Respir J 2012, 40(6):1516-1522.
9. Borghesi A., Massa M., Campanelli R., et al. Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2009, 180(6):540-546.
10. Popova A.P., Bozyk P.D., Bentley J.K., et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010, 126(5):e1127-e1133.
11. Bozyk P.D., Popova A.P., Bentley J.K., et al. Mesenchymal stromal cells from neonatal tracheal aspirates demonstrate a pattern of lung-specific gene expression. Stem Cells Dev 2011, 20(11):1995-2007.
12. Khwaja O., Volpe J.J. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 2008, 93(2):F153-F161.
13. Romanov Y.A., Darevskaya A.N., Merzlikina N.V., Buravkova L.B. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med 2005, 140(1):138-143.
14. Romanov Y.A., Svintsitskaya V.A., Smirnov V.N. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate msc-like cells from umbilical cord. Stem Cells 2003, 21(1):105-110.
15. Secco M., Zucconi E., Vieira N.M., et al. Multipotent stem cells from umbilical cord: cord is richer than blood!. Stem Cells 2008, 26(1):146-150.
16. Musina R.A., Bekchanova E.S., Sukhikh G.T. Comparison of mesenchymal stem cells obtained from different human tissues. Bull Exp Biol Med 2005, 139(4):504-509.
17. Peng L., Jia Z., Yin X., et al. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev 2008, 17(4):761-773.
18. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8(4):315-317.
19. Weiss D.J., Chambers D., Giangreco A., et al. An official american thoracic society workshop report: stem cells and cell therapies in lung biology and diseases. Ann Am Thorac Soc 2015, 12(4):S79-S97.
20. Jarvinen L., Badri L., Wettlaufer S., et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 2008, 181(6):4389-4396.
21. van Koppen A., Joles J.A., van Balkom B.W., et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One 2012, 7(6):e38746.
22. Schreml S., Babilas P., Fruth S., et al. Harvesting human adipose tissue-derived adult stem cells: resection versus liposuction. Cytotherapy 2009, 11(7):947-957.
23. de Sa Silva F., Almeida P.N., Rettore J.V., et al. Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy. J Biomed Biotechnol 2012, 2012:758102.
24. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11(5):321-334.
25. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105(5):2214-2219.
26. Duffy M.M., Ritter T., Ceredig R., Griffin M.D. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011, 2(4):34.
27. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated nk cells are capable of killing mscs, whereas mscs can inhibit il-2-induced nk-cell proliferation. Blood 2006, 107(4):1484-1490.
28. Jansen B.J., Gilissen C., Roelofs H., et al. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev 2010, 19(4):481-490.
29. Kuang P.P., Lucey E., Rishikof D.C., Humphries D.E., Bronsnick D., Goldstein R.H. Engraftment of neonatal lung fibroblasts into the normal and elastase-injured lung. Am J Respir Cell Mol Biol 2005, 33(4):371-377.
30. Tsai M.S., Hwang S.M., Chen K.D., et al. Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells 2007, 25(10):2511-2523.
31. Binato R., de Souza Fernandez T., Lazzarotto-Silva C., et al. Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif 2013, 46(1):10-22.
32. Foudah D., Redaelli S., Donzelli E., et al. Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res 2009, 17(8):1025-1039.
33. Zhou Y.F., Bosch-Marce M., Okuyama H., et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006, 66(22):10849-10854.
34. Aslam M., Baveja R., Liang O.D., et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009, 180(11):1122-1130.
35. Chang Y.S., Choi S.J., Sung D.K., et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011, 20(11-12):1843-1854.
36. van Haaften T., Byrne R., Bonnet S., et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009, 180(11):1131-1142.
37. Sutsko R.P., Young K.C., Ribeiro A., et al. Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. Pediatr Res 2013, 73(1):46-53.
38. Zhang X., Wang H., Shi Y., et al. Role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newborn mice. Cell Biol Int 2012, 36(6):589-594.
39. Chang Y.S., Oh W., Choi S.J., et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2009, 18(8):869-886.
40. Pierro M., Ionescu L., Montemurro T., et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013, 68(5):475-484.
41. Chang Y.S., Choi S.J., Ahn S.Y., et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One 2013, 8(1):e52419.
42. Hansmann G., Fernandez-Gonzalez A., Aslam M., et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ 2012, 2(2):170-181.
43. Islam M.N., Das S.R., Emin M.T., et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18(5):759-765.
44. Timmers L., Lim S.K., Arslan F., et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007, 1(2):129-137.
45. Kinnaird T., Stabile E., Burnett M.S., Epstein S.E. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 2004, 95(4):354-363.
46. Dorronsoro A., Robbins P.D. Regenerating the injured kidney with human umbilical cord mesenchymal stem cell-derived exosomes. Stem Cell Res Ther 2013, 4(2):39.
47. Tetta C., Bruno S., Fonsato V., Deregibus M.C., Camussi G. The role of microvesicles in tissue repair. Organogenesis 2011, 7(2):105-115.
48. Pisitkun T., Shen R.F., Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 2004, 101(36):13368-13373.
49. Pant S., Hilton H., Burczynski M.E. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012, 83(11):1484-1494.
50. Rana S., Zoller M. Exosome target cell selection and the importance of exosomal tetraspanins: a hypothesis. Biochem Soc Trans 2011, 39(2):559-562.
51. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of sirna to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29(4):341-345.
52. Cruz F.F., Borg Z.D., Goodwin M., et al. Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice. Stem Cells Transl Med 2015, 4(11):1302-1316.
53. Sung D.K., Chang Y.S., Ahn S.Y., et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology. PLoS One 2015, 10(8):e0135574.
54. Tibboel J., Keijzer R., Reiss I., de Jongste J.C., Post M. Intravenous and intratracheal mesenchymal stromal cell injection in a mouse model of pulmonary emphysema. COPD 2014, 11(3):310-318.
55. Bhatt A.J., Pryhuber G.S., Huyck H., Watkins R.H., Metlay L.A., Maniscalco W.M. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 164(10 Pt 1):1971-1980.
56. Thebaud B., Ladha F., Michelakis E.D., et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005, 112(16):2477-2486.
57. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
58. Ingram D.A., Mead L.E., Tanaka H., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104(9):2752-2760.
59. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109(5):1801-1809.
60. Balasubramaniam V., Ryan S.L., Seedorf G.J., et al. Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol 2010, 298(3):L315-L323.
61. Baker C.D., Seedorf G.J., Wisniewski B.L., et al. Endothelial colony-forming cell conditioned media promote angiogenesis in vitro and prevent pulmonary hypertension in experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2013, 305(1):L73-L81.
62. Alphonse R.S., Vadivel A., Fung M., et al. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014, 129(21):2144-2157.
63. Ilancheran S., Michalska A., Peh G., Wallace E.M., Pera M., Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 2007, 77(3):577-588.
64. Moodley Y., Ilancheran S., Samuel C., et al. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. Am J Respir Crit Care Med 2010, 182(5):643-651.
65. Vosdoganes P., Hodges R.J., Lim R., et al. Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep. Am J Obstet Gynecol 2011, 205(2):156.e126-156.e133.
66. Hodges R.J., Jenkin G., Hooper S.B., et al. Human amnion epithelial cells reduce ventilation-induced preterm lung injury in fetal sheep. Am J Obstet Gynecol 2012, 206(5):448.e8-448.e15.
67. Pawelec K., Gladysz D., Demkow U., Boruczkowski D. Stem cell experiments moves into clinic: new hope for children with bronchopulmonary dysplasia. Adv Exp Med Biol 2015, 839:47-53.
68. Sdrimas K., Kourembanas S. Msc microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal 2014, 21(13):1905-1915.
69. Weiss D.J. Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012. Ann Am Thorac Soc 2013, 10(5):S45-S97.
70. Wansleeben C., Barkauskas C.E., Rock J.R., Hogan B.L. Stem cells of the adult lung: their development and role in homeostasis, regeneration, and disease. Wiley Interdiscip Rev Dev Biol 2013, 2(1):131-148.
71. Borghesi A., Cova C., Gazzolo D., Stronati M. Stem cell therapy for neonatal diseases associated with preterm birth. J Clin Neonatol 2013, 2(1):1-7.
72. Fung M.E., Thebaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014, 75(1-1):2-7.
73. Foronjy R.F., Majka S.M. The potential for resident lung mesenchymal stem cells to promote functional tissue regeneration: understanding microenvironmental cues. Cells 2012, 1(4):874.
74. Jun D., Garat C., West J., et al. The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. Stem Cells 2011, 29(4):725-735.
75. Chow K., Fessel J.P., Kaoriihida S., et al. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. Pulm Circ 2013, 3(1):31-49.
76. Popova A.P., Bentley J.K., Anyanwu A.C., et al. Glycogen synthase kinase-3 beta/beta-catenin signaling regulates neonatal lung mesenchymal stromal cell myofibroblastic differentiation. Am J Physiol Lung Cell Mol Physiol 2012, 303(5):L439-L448.
77. Tropea K.A., Leder E., Aslam M., et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012, 302(9):L829-L837.
78. Titomanlio L., Kavelaars A., Dalous J., et al. Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann Neurol 2011, 70(5):698-712.
79. Verina T., Fatemi A., Johnston M.V., Comi A.M. Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatr Neurol 2013, 48(5):346-354.
80. Chicha L., Smith T., Guzman R. Stem cells for brain repair in neonatal hypoxia-ischemia. Childs Nerv Syst 2014, 30(1):37-46.
81. Carroll J. Human cord blood for the hypoxic-ischemic neonate. Pediatr Res 2012, 71(4 Pt 2):459-463.
82. Gonzales-Portillo G.S., Reyes S., Aguirre D., Pabon M.M., Borlongan C.V. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy. Front Neurol 2014, 5:147.
83. Fleiss B., Guillot P.V., Titomanlio L., Baud O., Hagberg H., Gressens P. Stem cell therapy for neonatal brain injury. Clin Perinatol 2014, 41(1):133-148.
84. Bennet L., Tan S., Van den Heuij L., et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Ann Neurol 2012, 71(5):589-600.
85. van Velthoven C.T., Kavelaars A., Heijnen C.J. Mesenchymal stem cells as a treatment for neonatal ischemic brain damage. Pediatr Res 2012, 71(4 pt 2):474-481.
86. Hegyi B., Kornyei Z., Ferenczi S., et al. Regulation of mouse microglia activation and effector functions by bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2014, 23(21):2600-2612.
87. Kim E.S., Ahn S.Y., Im G.H., et al. Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res 2012, 72(3):277-284.
88. Chen A., Siow B., Blamire A.M., Lako M., Clowry G.J. Transplantation of magnetically labeled mesenchymal stem cells in a model of perinatal brain injury. Stem Cell Res 2010, 5(3):255-266.
89. Lee J.A., Kim B.I., Jo C.H., et al. Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model. Pediatr Res 2010, 67(1):42-46.
90. Ohshima M., Taguchi A., Tsuda H., et al. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev 2015, 37(4):376-386.
91. Donega V., Nijboer C.H., van Velthoven C.T., et al. Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse. Pediatr Res 2015, 78(5):520-526.
92. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav Immun 2010, 24(3):387-393.
93. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 2010, 68(5):419-422.
94. van Velthoven C.T., van de Looij Y., Kavelaars A., et al. Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in mice. Ann Neurol 2012, 71(6):785-796.
95. Donega V., van Velthoven C.T., Nijboer C.H., et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One 2013, 8(1):e51253.
96. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J Neurosci 2010, 30(28):9603-9611.
97. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain. Brain Behav Immun 2011, 25(7):1342-1348.
98. Donega V., Nijboer C.H., Braccioli L., et al. Intranasal administration of human msc for ischemic brain injury in the mouse: in vitro and in vivo neuroregenerative functions. PLoS One 2014, 9(11):e112339.
99. van Velthoven C.T., Braccioli L., Willemen H.L., Kavelaars A., Heijnen C.J. Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage. Mol Ther 2014, 22(3):645-654.
100. van Velthoven C.T., Sheldon R.A., Kavelaars A., et al. Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke 2013, 44(5):1426-1432.
101. Park W.S., Sung S.I., Ahn S.Y., et al. Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS One 2015, 10(3):e0120893.
102. Abman S.H., Matthay M.A. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia: delivering the secretome. Am J Respir Crit Care Med 2009, 180(11):1039-1041.
103. Chen L., Wang Y., Pan Y., et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun 2013, 431(3):566-571.
104. Wei X., Du Z., Zhao L., et al. Ifats collection: the conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 2009, 27(2):478-488.
105. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289(1):F31-F42.
106. Nakagami H., Maeda K., Morishita R., et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005, 25(12):2542-2547.
107. Van Overstraeten-Schlogel N., Beguin Y., Gothot A. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. Eur J Haematol 2006, 76(6):488-493.
108. Ortiz L.A., Dutreil M., Fattman C., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007, 104(26):11002-11007.
109. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 2013, 95(12):2196-2211.
110. Lavoie J.R., Rosu-Myles M. Uncovering the secretes of mesenchymal stem cells. Biochimie 2013, 95(12):2212-2221.
111. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9(8):581-593.
112. Thery C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006, [chapter 3: unit] 3:22.
113. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2(8):569-579.
114. Segura E., Amigorena S., Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 2005, 35(2):89-93.
115. Barres C., Blanc L., Bette-Bobillo P., et al. Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood 2010, 115(3):696-705.
116. Tian T., Wang Y., Wang H., Zhu Z., Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J Cell Biochem 2010, 111(2):488-496.
117. Skog J., Wurdinger T., van Rijn S., et al. Glioblastoma microvesicles transport rna and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10(12):1470-1476.
118. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mrnas and micrornas is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):654-659.
119. Trams E.G., Lauter C.J., Salem N., Heine U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta 1981, 645(1):63-70.
120. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33(3):967-978.
121. Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987, 262(19):9412-9420.
122. Gould S.J., Booth A.M., Hildreth J.E. The trojan exosome hypothesis. Proc Natl Acad Sci U S A 2003, 100(19):10592-10597.
123. Kramer B., Pelchen-Matthews A., Deneka M., Garcia E., Piguet V., Marsh M. Hiv interaction with endosomes in macrophages and dendritic cells. Blood Cells Mol Dis 2005, 35(2):136-142.
124. Wurdinger T., Gatson N.N., Balaj L., Kaur B., Breakefield X.O., Pegtel D.M. Extracellular vesicles and their convergence with viral pathways. Adv Virol 2012, 2012:767694.
125. Kitazawa Y., Li X.K., Xie L., Zhu P., Kimura H., Takahara S. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats. Cell Transplant 2012, 21(2-3):581-590.
126. Budoni M., Fierabracci A., Luciano R., Petrini S., Di Ciommo V., Muraca M. The immunosuppressive effect of mesenchymal stromal cells on b lymphocytes is mediated by membrane vesicles. Cell Transplant 2013, 22(2):369-379.
127. Peche H., Heslan M., Usal C., Amigorena S., Cuturi M.C. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 2003, 76(10):1503-1510.
128. Lee C., Mitsialis S.A., Aslam M., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126(22):2601-2611.
129. Parekkadan B., van Poll D., Suganuma K., et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007, 2(9):e941.
130. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10(3):244-258.
131. Baglio S.R., Pegtel D.M., Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 2012, 3:359.
132. Yeo R.W., Lai R.C., Zhang B., et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 2013, 65(3):336-341.
133. Lai R.C., Arslan F., Lee M.M., et al. Exosome secreted by msc reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010, 4(3):214-222.
134. Zhou Y., Xu H., Xu W., et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 2013, 4(2):34.
135. Bruno S., Grange C., Deregibus M.C., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20(5):1053-1067.
136. Liu G.S., Thornton J., Van Winkle D.M., Stanley A.W., Olsson R.A., Downey J.M. Protection against infarction afforded by preconditioning is mediated by a1 adenosine receptors in rabbit heart. Circulation 1991, 84(1):350-356.
137. Kitakaze M., Hori M., Takashima S., Sato H., Inoue M., Kamada T. Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation 1993, 87(1):208-215.
138. Arslan F., Lai R.C., Smeets M.B., et al. Mesenchymal stem cell-derived exosomes increase atp levels, decrease oxidative stress and activate pi3k/akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 2013, 10(3):301-312.
139. Ranghino A., Cantaluppi V., Grange C., et al. Endothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia. Int J Immunopathol Pharmacol 2012, 25(1):75-85.
140. Deregibus M.C., Cantaluppi V., Calogero R., et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mrna. Blood 2007, 110(7):2440-2448.
141. Gatti S., Bruno S., Deregibus M.C., et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011, 26(5):1474-1483.
142. Cantaluppi V., Gatti S., Medica D., et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microrna-dependent reprogramming of resident renal cells. Kidney Int 2012, 82(4):412-427.
143. Khan M., Nickoloff E., Abramova T., et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res 2015, 117(1):52-64.
144. Zhang Y., Chopp M., Meng Y., et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg 2015, 122(4):856-867.
145. Doeppner T.R., Herz J., Gorgens A., et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med 2015, 4(10):1131-1143.
146. Trounson A., McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015, 17(1):11-22.
147. Ahn S.Y., Chang Y.S., Park W.S. Stem cell therapy for bronchopulmonary dysplasia: bench to bedside translation. J Korean Med Sci 2015, 30(5):509-513.
148. Chang Y.S., Ahn S.Y., Yoo H.S., et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014, 164(5):966-972.e6.
149. Cotten C.M., Murtha A.P., Goldberg R.N., et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr 2014, 164(5):973-979.e1.
150. Lalu M.M., McIntyre L., Pugliese C., et al. Safety of cell therapy with mesenchymal stromal cells (safecell): a systematic review and meta-analysis of clinical trials. PLoS One 2012, 7(10):e47559.